Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more
Pmv Pharmaceuticals Inc (PMVP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.164x
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has a cash flow conversion efficiency ratio of -0.164x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.82 Million) by net assets ($121.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pmv Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pmv Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PLAYWAY SA
WAR:PLW
|
0.071x |
|
Arverne Group S.A.
F:5H1
|
N/A |
|
CNB Bank Shares Inc
OTCQX:CNBN
|
0.030x |
|
Zeus Co.Ltd
KQ:079370
|
0.063x |
|
AZKOYEN SA INH. EO 060
F:AKK
|
N/A |
|
Leo Systems
TWO:5410
|
0.448x |
|
Ucore Rare Metals Inc
OTCQX:UURAF
|
-0.027x |
|
Major Cineplex Group Public Company Limited
F:MJG1
|
0.055x |
Annual Cash Flow Conversion Efficiency for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pmv Pharmaceuticals Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $104.71 Million | $-73.58 Million | -0.703x | -141.26% |
| 2024-12-31 | $176.08 Million | $-51.28 Million | -0.291x | -18.10% |
| 2023-12-31 | $225.69 Million | $-55.66 Million | -0.247x | +4.84% |
| 2022-12-31 | $246.03 Million | $-63.76 Million | -0.259x | -71.71% |
| 2021-12-31 | $308.56 Million | $-46.57 Million | -0.151x | -65.56% |
| 2020-12-31 | $359.12 Million | $-32.74 Million | -0.091x | -129.12% |
| 2019-12-31 | $-70.47 Million | $-22.07 Million | 0.313x | -4.82% |
| 2018-12-31 | $-46.14 Million | $-15.18 Million | 0.329x | -- |